Skip to main content

Table 8 Longitudinal, terminal and histological measurements after in vivo pravastatin treatment

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

  CKD ( n = 6) CKD + pravastatin ( n = 5)
Focal glomerulosclerosis (%)   
 Normal 32.9 ± 7.6 23.4 ± 13.1
 Partial 48.1 ± 10.6 62.7 ± 10.4
 Total 19.0 ± 6.7 14.0 ± 15.8
Tubulo-interstitial damage   
 Fibrosis 0.78 ± 0.31 0.85 ± 0.14
 Inflammation 1.72 ± 0.54 1.66 ± 0.22
 Atrophy 1.09 ± 0.65 0.56 ± 0.09
  1. Data presented as mean ± standard deviation. CKD, chronic kidney disease.